Ordering Recommendation

Consider ordering for individuals with paraneoplastic encephalomyelitis, chorea, cerebellar degeneration, optic neuritis, and peripheral neuropathy. May aid in diagnosis of occult or recurrent tumor.

Mnemonic

CV2.1 SCRN

Methodology

Semi-Quantitative Indirect Fluorescent Antibody

Performed

Thu

Reported

1-8 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation
Collect

Serum Separator Tube (SST) or Plain Red

Specimen Preparation

Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.25 mL)

Storage/Transport Temperature

Refrigerated

Unacceptable Conditions

Hemolyzed, contaminated, or severely lipemic specimens

Remarks
Stability

Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year

Reference Interval

Less than 1:10

Interpretive Data

CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

If CV2.1 Antibody IgG Screen by IFA is positive, then CV2.1 Antibody IgG Titer by IFA will be added. Additional charges apply.

Hotline History

N/A

CPT Codes

86255; if reflexed, add 86256

Components

Component Test Code* Component Chart Name LOINC
2013959 CV2.1 Antibody IgG Screen by IFA 72504-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

CV2.1 Screen by IFA with Reflex to Titer